UBS Maintains a 'Neutral' on Cepheid (CPHD); High Quality Finish to 2011

UBS maintains a 'Neutral' on Cepheid (NASDAQ: CPHD) price target raised from $40 to $45.

UBS analyst said, "Top & bottom line beat, with solid sales guidance for ’12...For ’12, mgmt sees sales of $333-347M (vs. Street $333/UBSe $334) and adjusted EPS of $0.18-$0.23 (Street $0.40). For ’12-‘13 we now see revs of $340M and $413M (vs. prior $333M & $407M), respectively, with adjusted EPS of $0.20 (was $0.46) and $0.49 (was $0.80) – reduced due to lower gross margin estimates."

For an analyst ratings summary and ratings history on Cepheid click here. For more ratings news on Cepheid click here.

Shares of Cepheid closed at $34.35 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• DA Davidson Reiterates Neutral Rating on Timken (TKR)
• New Street Research Upgrades Micron Technology (MU) to Buy